+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors for dysplasia in patients with Barretts esophagus Results from a multicenter consortium



Risk factors for dysplasia in patients with Barretts esophagus Results from a multicenter consortium



Gastroenterology 116(4 Part 2): A175




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035672741

Download citation: RISBibTeXText


Related references

Risk factors for dysplasia in patients with Barrett's esophagus (BE): Results from a multicenter consortium. Digestive Diseases and Sciences 48(8): 1537-1541, 2003

Analysis of Barretts esophagus causes and risk factors for dysplasia and drug treatment to reverse dysplasia in Barretts esophagus. American Journal of Gastroenterology 98(9 Suppl.): S27, 2003

1080 - Dysplasia Free Survival in Patients with Barrett's Esophagus after Successful Endoscopic Therapy: Results from a Large Multicenter Consortium. Gastroenterology 154(6): S-209-S-210, 2018

Expression of trefoil factors in Barretts esophagus, dysplasia and adenocarcinoma arising in Barretts. Laboratory Investigation 82(1): 124A-125A, 2002

Risk factors for developing dysplasia or adenocarcinoma in Barretts esophagus with implications for endoscopic surveillance. Gastroenterology. 106(4 Suppl.): A45, 1994

Su1119 Complete Eradication Of Intestinal Metaplasia And Dysplasia After Multi-Modality Endoscopic Therapy For Dysplastic BarrettS Esophagus (Be) With Visible Mucosal Lesions: Results From A Multi-Center Consortium. Gastrointestinal Endoscopy 87(6): Ab280-Ab281, 2018

A multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy using porfimer sodium for the ablation of high-grade dysplasia in Barretts esophagus Results of 6-month follow-up. Gastroenterology 120(5 Suppl. 1): A 79, 2001

International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy using porfimer sodium for the ablation of high grade dysplasia in barretts esophagus results of 24 month follow up. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 151, 2003

Barretts esophagus with severe dysplasia or early cancer Results of endoscopic mucosectomy in 17 patients. Gastroenterology 118(4 Suppl 2 Part 1): A221, 2000

Reproducibility of the diagnosis of dysplasia in Barretts esophagus A multicenter study of 125 mucosal biopsies by 12 observers. Modern Pathology 12(1): 80A, 1999

Tu1102 Are Clinical Outcomes in Indefinite for Dysplasia (IND) Any Different From Low Grade Dysplasia (LGD) in Patients With Barrett's Esophagus (BE)? Results From a Large Multicenter Cohort Study. Gastroenterology 142(5): S-746-S-747, 2012

Proton Pump Inhibitor Use but Not Statin Use Is Associated With Decreased Risk for High-grade Dysplasia and Esophageal Adenocarcinoma in Patients With Barrett's Esophagus: Results From a Large, Multicenter Cohort Study. Gastroenterology 146(5): S-123, 2014

T1932 Basal Crypt Dysplasia Is Highly Associated with Conventional Dysplasia in Barretts Esophagus: A Seattle Cohort Study of 101 Patients. Gastroenterology 136(5): A-603, 2009

Incidence of high grade dysplasia/adenocarcinoma in Barretts esophagus A propective study in a low risk country for adenocarcinoma of the esophagus. Gastroenterology 118(4 Suppl 2 Part 1): A38, 2000

An attempt to identify risk factors for development of adenocarcinoma in patients with Barretts esophagus. Gastroenterology 108(4 Suppl. ): A34, 1995